Login to Your Account



DOR's OrBec Not Approvable; FDA Wants More GVHD Data

By Jennifer Boggs


Monday, October 22, 2007
Under-a-dollar shares of DOR BioPharma Inc. lost more than half their value after the FDA issued a not approvable letter for orBec, a steroid-sparing agent, citing the need for further efficacy and safety data in patients with gastrointestinal graft-vs.-host disease, a complication of hematopoietic cell transplantation. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription